CCR3: Früherkennung und Therapie der feuchten Makuladegeneration (AMD) zukünftig erleichtert

A New Target for Neovascular AMD

Since the middle of the last decade, pharmacotherapy has transformed the management of neovascular age-related macular degeneration (AMD). Specifically, the ability to pharmacologically inhibit vascular endothelial growth factor (VEGF) has changed the prognosis of neovascular AMD from one of laser photocoagulation and observation of progressively worsening vision to the current paradigm of stabilization or improvement of vision for most patients with repeated intravitreal injections of an anti-VEGF agent.

CCR3: Shedding New Light on a Dark Problem?

A recent work by Ambati et al. represents a bold step towards a more effective diagnosis and treatment of age-related macular degeneration, with the new evidence showing that CCR3, a chemokine receptor, is an early marker of and potential therapeutic target for choroidal neovascularization development.

Erstmals eindeutiges molekulares Kennzeichen für AMD gefunden

Die altersbedingte Makuladegeneration (AMD) lässt sich künftig möglicherweise früher feststellen und auch besser behandeln.

UK leads on eye disease discoveries

Discoveries by University of Kentucky researchers potentially could lead to a new way of simultaneously detecting and treating a type of macular degeneration

Nowe spojrzenie na poważną chorobę oczu

Receptor o nazwie CCR3 jest odpowiedzialny za rozwój związanego z wiekiem zwyrodnienia plamki żółtej i może stanowić dobry marker diagnostyczny tej choroby

Durchbruch gegen Hauptursache für Erblindungen

Früherkennung und Therapie der feuchten Makuladegeneration (AMD) zukünftig erleichtert

Nuove possibilità nella diagnosi e cura della degenerazione maculare

Bloccare una proteina per ridurre la crescita anormale dei vasi sanguigni

Breakthrough In Early Detection And Prevention Of Age-related Macular Degeneration

Researchers at the University of North Carolina at Chapel Hill School of Medicine in collaboration with lead investigators at the University of Kentucky have identified a new target for the diagnosis and treatment of age-related macular degeneration

AMD: Neuer Therapieansatz im Frühstadium

US-Forscher haben offenbar einen wichtigen Antreiber für die choroidale Neovaskularisation gefunden, die der altersabhängigen Makuladegeneration (AMD) zugrunde liegt, der häufigsten Ursache für Erblindungen im Alter.

Auge: Neue Hoffnung bei Makuladegeneration

Forscher haben ein vielversprechendes Eiweiß gefunden, das die Therapie von AMD verbessern könnte

研究发现黄斑变性新靶标CCR3

北卡罗莱纳大学医学院研究人员确定了诊断和治疗年龄相关性黄斑变性新靶标，该病是美国老年人最常见的失明原因

Age-Related Macular Degeneration Halted by Blocking Protein to Stop Blood Vessel Growth

Protein CCR3 a new target for diagnosis and treatment of AMD, the most common cause of blindness in senior citizens.

Major Breakthrough in Early Detection and Prevention of AMD

A team of researchers led by Dr. Jayakrishna Ambati at the University of Kentucky has discovered a biological marker for neovascular age-related macular degeneration (AMD), the leading cause of blindness in older adults.

Identifican una diana terapéutica para la ceguera asociada a la edad

Investigadores de la Universidad de Kentucky en Lexington (Estados Unidos) han identificado un posible marcador para detectar la degeneración macular asociada a la edad (DMAE)

Study suggests new approach to common cause of blindness

Researchers at the University of North Carolina at Chapel Hill School of Medicine in collaboration with lead investigators at the University of Kentucky have identified a new target for the diagnosis and treatment of age-related macular degeneration, the most common cause of blindness in older Americans.